Select your localized edition:

Close ×

More Ways to Connect

Discover one of our 28 local entrepreneurial communities »

Be the first to know as we launch in new countries and markets around the globe.

Interested in bringing MIT Technology Review to your local market?

MIT Technology ReviewMIT Technology Review - logo

 

Unsupported browser: Your browser does not meet modern web standards. See how it scores »

{ action.text }

Our September issue reports the discontinuation of the human trials Avigen was conducting on a new hemophilia treatment–the latest of many setbacks in the commercialization of gene therapy. But basic research in the field has continued undaunted, with results that may strike you as either astounding or terrifying, depending on how you feel about the prospect of genetically modifying your personality.

Researchers at the National Institute of Mental Health have used gene therapy to “cure” monkeys of their tendency to procrastinate. Similar treatments could eventually benefit people suffering from depression, schizophrenia, and obsessive-compulsive disorder; but they could also take the debate about the “medicalization” of psychological characteristics into a whole new arena.

0 comments about this story. Start the discussion »

Reprints and Permissions | Send feedback to the editor

From the Archives

Close

Introducing MIT Technology Review Insider.

Already a Magazine subscriber?

You're automatically an Insider. It's easy to activate or upgrade your account.

Activate Your Account

Become an Insider

It's the new way to subscribe. Get even more of the tech news, research, and discoveries you crave.

Sign Up

Learn More

Find out why MIT Technology Review Insider is for you and explore your options.

Show Me